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Background: OptiScanner devices, continuous glucose monitoring devices that perform automated blood draws
via a central venous catheter and create plasma through centrifugation, measure plasma glucose levels through
mid-infrared spectroscopy at the bedside. The objective of this study was to determine accuracy and practicality of
the devices in critically ill patients attempting glycemic control.
Methods: The plasma glucose level was measured by the devices and in comparative plasma samples using Yellow
Springs Instrument (YSI) plasma analyzers. After adding several previously unrecognized interferences in the
interference library, we reanalyzed the mid-infrared signals and compared the resulting plasma glucose level with
the reference value. Results are presented in Clarke error grids, glucose prediction errors and Bland-Altman plots
and expressed as correlation coefficients.
Results: We analyzed 463 comparative samples from 71 patients (median 6 (4 to 9) samples per patient). After
calibrating the system, a Clarke error grid showed 100% of the values in zones A or B. The glucose predictor error
demonstrated that 86% of the glucose values < 75 mg/dL were within ± 15 mg/dL of the YSI results and 95% ≥ 75
mg/dL were within 20% of the comparative YSI results. Bland-Altman plot showed a bias of −0.6 with limit of
agreement of −24.6 to 23.3. The Pearson correlation coefficient was 0.93 and R2 was 0.87. In one third of the patients
the devices had to be disconnected prematurely (that is before planned disconnection) because of repeated occlusion
alarms suggesting blood draw errors.
Conclusion: The devices needed calibration for several previously unrecognized interferences. Thereafter, accuracy of
the device to measure plasma glucose levels in ‘our cohort’ of critically ill patients improved, but external validation is
highly recommended. The automated blood draw system of the devices needs further improvement to make this
device of value for clinical use (trial registration (Netherlands Trial Register): NTR2864).
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Critically ill patients often receive insulin infusion [1,2],
although concerns with the risk of hypoglycemia and
failure to show a positive impact on patient outcome has
altered the frequency of use. Intense monitoring of the
blood glucose level is a prerequisite for efficient and safe* Correspondence: r.t.vanhooijdonk@amc.uva.nl
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reproduction in any medium, provided the originsulin infusion [1,2]. At present, ICU nurses monitor
the blood glucose level through intermittent manually
obtained blood samples for glucose measurements in
central laboratories or at the bedside using different
types of point-of-care analyzers [3].
Today’s blood glucose monitoring suffers from a var-
iety of error sources that can put ICU patients at risk for
insulin titration inaccuracies [4]. Moreover, intermittent
glucose monitoring lacks sufficient trending, while im-
mediate feedback and predictability of the effects of in-
sulin could have the potential to improve titration ofThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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take > 2 mL of blood with every blood draw and the time
consumed is estimated to be as high as five minutes with
each draw and subsequent measurement [6], which makes
intense monitoring impractical if not impossible. Auto-
mated continuous glucose monitoring (CGM) could over-
come several of these problems.
OptiScanner devices (OptiScan Biomedical Corporation,
Hayward, CA, USA), devices that perform automated
blood draws via central venous catheters and create
plasma through automatic centrifugation, measure the
plasma glucose level every 15 minutes through mid-
infrared spectroscopy at the bedside [7]. In a pre-
clinical animal study, this device accurately measured
the glucose level along hypoglycemic, euglycemic and
hyperglycemic ranges [7]. Similar results came from a
study with diabetic volunteers [8], and a study of fro-
zen and stored plasma samples from critically ill pa-
tients [9]. We hypothesized that the devices provide
accurate glucose level measurements in ICU patients.
In this study we tested the accuracy of the devices in a
cohort of critically ill patients treated according to a
glucose control guideline targeting blood glucose levels
between 90 and 144 mg/dL (ICU-A in [10]).
Methods
Study design and informed consent
This was an investigator-initiated observational study
testing the accuracy of the devices in critically ill pa-
tients. OptiScan Biomedical Corporation sponsored part
of the study, identified interferences and updated the
interference library. The company had no influence on
study design, the final analysis and the writing of this
manuscript. The Institutional Review Board of the
Academic Medical Center (AMC), Amsterdam, the
Netherlands, approved the study protocol. Patients or
next of kin had to provide written informed consent
before the start of any procedure of the study. Analysis
of paired data followed the analysis plan as published
at [http://www.trialregister.nl/] (NTR2864).
Study location
The study was performed in a 32-bed mixed medical-
surgical ICU in a university hospital (AMC), a closed
format department with patients under the direct care
of an ICU team. The nurse to patient ratio is 1:2. All beds
are equipped with a patient data management system
(MetaVision®, iMDsoft, Tel Aviv, Israel) in which all
clinical and laboratory data are stored.
Study population
Patients were eligible for inclusion if they were aged ≥ 18
years, had an expected ICU length of stay of > three days
at time of enrollment and an Acute Physiology and ChronicHealth Evaluation (APACHE) II [11] score ≥ 10, had an
existing arterial line, and had an existing central venous
catheter (CVC) with a free lumen available. Both pa-
tients who received insulin infusion and patients who
did not receive insulin infusion could be included in the
study. Patients were excluded if they had received any
investigational product or if they had received treatment
with an investigational device within the previous 30
days or were pregnant. For practical reasons, patients in
isolation for colonization with multi-resistant bacteria
were excluded from participation.
ICU nurses performed glucose control with insulin,
following a local guideline targeting at blood glucose
levels between 90 and 144 mg/dL (ICU-A in [10]). The
local guideline for glucose control advised starting con-
tinuous infusion of insulin when the blood glucose
level > 144 mg/dL. Insulin was exclusively given by con-
tinuous intravenous infusion with only a bolus of insulin
given when the blood glucose level exceeded > 360 mg/dL.
Subcutaneous insulin is never used. Insulin infusion ad-
justments were made using sliding scales [10]. Insulin in-
fusion was stopped and boluses of dextrose were given
when the blood glucose level declined < 61 mg/dL. Ac-
cording to the local guideline for glucose control, glucose
levels were to be measured at least every four hours, but
for the study the study protocol dictated that comparative
glucose levels were to be measured every two hours. Glu-
cose levels used for insulin adjustment were measured in
arterial blood samples using RapidLab 1265 blood gas an-
alyzers (Siemens Healthcare Diagnostics, The Hague, the
Netherlands), located in the ICU.OptiScanner
The device withdraws approximately 2.6 mL of blood
every 15 minutes. From this, a sample of approximately
0.1 mL is extracted, heparinized, converted to plasma
and analyzed by a mid-infrared spectrometer. For this,
after each draw, the device centrifuges the sample, and a
measurement is conducted on the plasma component
using spectral analysis. This spectroscopy technique is
based on the characteristic absorption of vibrational
nodes of different molecules, including glucose. Mid-
infrared spectroscopy can be used because the glucose
spectral peaks are in the mid-infrared region [7]. After
measurement, the device automatically flushes the
sample to sealed waste containers, cleaning the micro-
cuvette in the process. The remaining approximate 2.5 mL
of blood is returned back to the patient with a small
amount of saline (less than 2.0 mL). There is no heparin
in the blood that is returned to the patient. The devices
have an onboard interference library which includes drugs
and endogenous substances that is used to subtract out
interferences.
Figure 1 An example of a patient without interferences (upper
panel) and of a patient with non-physiological glucose changes
caused by simultaneous infusion of parenteral nutrition
(lower panel).
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One device was connected to the proximal port of an
existing CVC for up to 24 hours in the first 65 patients,
and for up to 72 hours in the last 10 patients. Every 15
minutes, the device withdrew blood and measured the
plasma glucose level. These results were not visible for
ICU nurses and staff, but were downloaded to a com-
puter after disconnection of the device. Comparative ar-
terial blood draws were taken every two hours, at the
same time as the device was drawing venous blood,
starting from approximately 8 am until 10 pm. Com-
parative glucose levels in plasma were measured imme-
diately with the YSI 2300 STAT Plus (Yellow Springs
Instrument, Yellow Springs, OH, USA) and with the
RapidLab 1265 blood gas analyzers (Siemens Healthcare
Diagnostics, The Hague, the Netherlands). The results
of the blood gas analyzers were available for the nurses
for insulin titration.
Dealing with new interfering substances
An interfering substance was suspected if we found sig-
nificant discrepancies between paired fixed-wavelength
mid-infrared glucose measurements and YSI readings.
OptiScan Biomedical Corporation then analyzed the
source documentation to identify what substances could
have affected the spectra. Pure spectra of the identified
interferences were then isolated and subsequently proven
to interfere in separate laboratory experimentation by
OptiScan Biomedical Corporation. If subsequently veri-
fied, the interference was added to the interference library.
First, the updated interference library was tested in the
already collected spectroscopies. Thereafter, the interfer-
ence library was updated to the onboard database and
used in subsequent patients.
The onboard interference library was updated twice
during the study, that is after inclusion and analysis of
patient 28 and patient 63, and once after inclusion of the
last patient. We thus had accrued three different inter-
ference libraries during the study, and one new interfer-
ence library at the end of the study. After adding all
validated interferences in the interference library, the
mid-infrared spectroscopies were reanalyzed by OptiS-
can Biomedical Corporation, calculating a new glucose
value for every collected spectroscopy.
Statistical analysis
In two patients, we detected frequent non-physiological
glucose changes, defined as increases and/or decreases
of the glucose level more than 80 mg/dL in consecutive
device-readings while insulin infusion rates were not al-
tered. These non-physiological glucose changes were
caused by simultaneous intravenous infusion of 5% dex-
trose in one patient, and parenteral nutrition in another
patient via another lumen of the CVC. Therefore thesetwo patients were excluded for analysis. Figure 1 shows
an example of a patient without interferences and a pa-
tient with non-physiological glucose changes in a patient
who received parenteral nutrition via another lumen of
the CVC used for sampling by the device.
We report data as means (± SD) or medians (IQR)
where appropriate. In order to be considered for the
statistical analysis, each patient needed to have at least
two consecutive and successfully analyzed blood draws.
Clarke error grid (CEG) analyses were used to show
the percentage of paired values falling within predefined
zones. The CEG is divided in ten zones: in the two zones
A the device results are < 20% of the YSI results, which
is seen as clinical acceptable, or the results are < 70 mg/dL;
in the two zones B the device results deviate > 20% from
the YSI result, but deviations are seen as clinically ac-
ceptable because they are considered only to cause be-
nign insulin titration errors; in the zones C to E the
deviations become increasingly unacceptable; in zones
D potentially dangerous hypoglycemia or hyperglycemia
are left undetected, and in zones E device results lead to
opposite treatment decisions, that is the device suggests
Figure 2 CONSORT diagram of the study.
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versa [12].
For each pair of device and YSI results, the glucose
prediction error was defined as (device result – YSI result).
The percentage of paired data points with glucose predic-
tion errors are presented according to the current Inter-
national Standards Organization standard (ISO15197),
with the percentage of data points specified that fall
within ± 15 mg/dL of the YSI results for YSI glucose level
of < 75 mg/dL, and within ± 20% of the YSI results for YSI
glucose level ≥ 75 mg/dL. The higher the percentages, the
better accuracy for YSI results < 75 mg/dL, or ≥ 75 mg/dL.
Bland-Altman plot with bias (mean difference between
the device and YSI measurements) and limits of agree-
ment (bias ± 1.96 x standard deviation of the bias) were
used to show agreement between the device and YSI
measurements [13]. The limit of agreement shows the
band in which 95% of the device results deviate from the
mean difference between the YSI and device results. The
smaller the bias and limit of agreement, the better agree-
ment between the YSI and device results [13].
The results of the device were regressed on the results
of the YSI using unweighted least squares. The linearity
between the device and the YSI over the study measure-
ment range were assessed by the Pearson correlation co-
efficient and coefficient of determination, R2.
To assess if the occurrence of occlusion alarms was
related to the insertion site of the CVC, patients were
divided into groups based on the location of their CVC
(jugular, femoral or subclavian). The Chi-square test
was used to compare the different locations with and
without alarms. A P-value < 0.05 was considered statisti-
cally significant.
Analyses were performed using IBM SPSS Statistics 20
(IBM, Armonk, New York, United States). R (version:
2.15.1; R Foundation for Statistical Computing, Vienna,
Austria) was used for CEG, glucose prediction error,
Bland-Altman plot and linearity tests.
Results
Patients
We included 75 patients (Figure 2). Two patients from
whom non-physiological blood glucose changes were
noted and two patients, from whom we could not collect
the minimum number of two consecutive blood draws,
were excluded from the analysis.
Patient characteristics and metrics of glucose control
are shown in Tables 1 and 2. The median connection time
was 22.9 (11.4 to 24) hours for patients planned to be con-
nected up to 24 hours and 28.4 (3.2 to 63.3) for the final
ten patients planned to be connect up to 72 hours. In
total, we used 101 cartridges (median 1 (1 to 2) per patient
planned to be connected up to 24 hours; median 1 (1 to
2.25) per patient connected up to 72 hours).Accuracy of devices in critically ill patients
We collected 168 paired samples in 27 patients using
interference library 1, 168 paired samples in 32 pa-
tients using interference library 2, and 98 paired sam-
ples in 12 patients using interference library 3. CEGs
(Figure 3), glucose predictor error (Figure 3) and
Bland-Altman plot (Figure 3) demonstrated that the
accuracy of the device improved with the two updates
of the interference libraries. Indeed, the percentage
of paired samples in zones B and C of the CEG de-
creased with successive updates. In accordance, the
glucose prediction errors and Bland-Altman plots
showed an improved accuracy and a smaller bias and
limits of agreement. The Pearson correlation coeffi-
cient and R2 increased from 0.80 and 0.63 (with
interference library 1), to 0.82 and 0.67 (with interfer-
ence library 2) and 0.93 and 0.88 (with interference
library 3).
With the recalculated values we analyzed all paired
samples (Figure 3). The correlation coefficient was 0.93
and R2 was 0.87. The accuracy of the results of the final
12 patients was consistent with the reanalysis by
OptiScan Biomedical Corporation of the overall study
population.
Table 2 Measures of blood glucose control
Number of measurements 484
Blood glucose level - mg/dL (median (IQR)) 130.3 (113.0 to
147.3)
Blood glucose level - mg/dL (mean ± SD) 134.3 ± 35.0
Number of measurements
per patient (median, IQR)
6 (4 to 9)
Severe hypoglycemia < 40 mg/dL - measurements,
number (%)
0
Severe hypoglycemia < 40 mg/dL - patients,
number (%)
0
Mild hypoglycemia < 75 mg/dL - measurements,
number (%)
8 (1.7%)
Mild hypoglycemia < 75 mg/dL - patients,
number (%)
5 (7.0%)
Mild hyperglycemia > 150 mg/dL - measurements,
number (%)
110 (22.7%)
Mild hyperglycemia > 150 mg/dL - patients,
number (%)
36 (50.7%)
Severe hyperglycemia > 180 mg/dL - measurements,
number (%)
42 (8.7%)
Severe hyperglycemia > 180 mg/dL - patients,
number (%)
13 (18.3%)
Data consider the period of the study to be from when the OptiScanner®
was connected.
Table 1 Patient characteristics
Age (years), median (IQR) 65 (55 to 73)
Male gender, number (%) 44 (62)
Admission diagnosis, number (%)
Medical 42 (59.2)
Surgical 18 (40.8)
Unplanned admission 56 (78.9)
APACHE II scores, median (IQR)_ 21 (16 to 26)
SAPS II, median (IQR) 43 (36 to 54)
ICU LOS (days), median (IQR) 10 (5 to 20)
Hospital LOS (days), median (IQR) 20 (12 to 34)
ICU mortality, number (%) 16 (22.5)
Hospital mortality, number (%) 20 (28.2)




Type of central venous catheter, number (%)
Trilumen 23 (32.4)
Quad lumen 48 (67.6)
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, BMI
body-mass index, ICU intensive care unit, IQR interquartile range, LOS length of
stay, SAPS Simplified Acute Physiology Score.
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We found the following interferences; 6% hydroxyethyl
starch (Venofundin®, B Braun, Melsungen, Germany);
20% human albumin (Albuman®, Sanquin, Amsterdam,
the Netherlands, immunoglobulin G (Nanogam®, Sanquin,
Amsterdam, the Netherlands), propofol (Propofol-®Lipuro,
B Braun, Melsungen, Germany), cephalosporin (including
cefotaxim and ceftazidim), lactate (infusion fluid contain-
ing lactate used for continuous veno-venous hemofiltra-
tion), mannitol and infusion of phosphate (Figure 1).
Practicality of the devices in critically ill patients
The device was prematurely disconnected (that is, before
24 hours in the first 65 patients, or before 72 hours in
the remaining 10 patients) in 8 patients because of early
patient discharge, death, or the necessity to use the
lumen of the CVC for infusion of medication, and in 26
patients because of device errors (two patients) or prob-
lems with withdrawal of blood from the central venous
line. In 32 patients occlusion alarms occurred, suggest-
ing that the devices could not draw blood from the CVC
(Table 3). In eight patients this alarm was solved through
flushing the connection system. In 24 patients, this
alarm could not be solved and the device was discon-
nected. The occurrence of occlusion alarms was inde-
pendent of the insertion site of the CVC (femoral versus
jugular versus subclavian) or type of CVC (trilumen ver-
sus quad lumen).
In 18 out of 101 (18%) cartridges an error occurred,
mandating replacement of the cartridge. Twelve cart-
ridge failures occurred prior to connecting the device to
the patient, that is during the systems initial self-
diagnostic check of the system. After connection, in four
cases there was a problem with the fluidics system
within the cartridge; in one case blood could not be
drawn and in one case there was a problem with loading
heparin into the cartridge. A system error, mandating a
reset of the system, occurred three times. In all cases
this happened before connection of the device to the pa-
tient. We could not further determine what actually hap-
pened, because the logging capabilities failed to analyze
this error.
Discussion
The present study shows that the device, after calibra-
tion for previously unrecognized interferences, had a
better accuracy for measuring plasma glucose levels in
critically ill patients. However, in a significant number of
patients the devices had to be disconnected prematurely
because of occlusion alarms, which could not easily be
overcome by flushing the system.
The results of the present investigation confirm find-
ings from previous studies with the same devices. One
study of otherwise healthy diabetic patients showed 99%





Total alarms 32 (45%) 36 (36%)
Per insertion site
Femoral 14 (47%) 17 (42%)
Jugular 12 (40%) 13 (30%)
Subclavian 6 (55%) 6 (35%)
Per type of central venous
catheter
Trilumen 14 (61%) 15 (52%)
Quad lumen 18 (38%) 21 (29%)
Alarms leading to
disconnection
24 (34%) 24 (24%)
Per insertion site
Femoral 12 (40%) 12 (29%)
Jugular 8 (27%) 8 (19%)
Subclavian 4 (37%) 4 (24%)
Per type of central venous
catheter
Trilumen 11 (48%) 11 (38%)
Quad lumen 13 (27%) 13 (18%)
Figure 3 Bland-Altman plot (upper left panels), glucose prediction error (left lower panels) and Clarke error grid (right panels) for
patients 1 to 28 using interference library 1 (left upper box), for patients 29 to 63 using interference library 2 (right upper box) and
patients 64 to 75 using interference library 3 (left lower box). The paired samples of all patients together (that is, patients 1 – 28 + 29 – 63 + 64 –75)
were recalculated using interference library 4 (right lower box).
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study testing ex vivo point accuracy of the same devices
using frozen plasma samples from a series of ICU pa-
tients found a correlation coefficient of 0.94 [9]. While
the device was designed for critically ill patients it had
not yet been tested in vivo, and specifically, in critically
ill patients at the ICU bedside. The present study expands
the experience with the devices and shows that the devices
could perform accurate glucose level measurements.
The accuracy of the device improved after adding inter-
ferences to the interference library. Indeed, after adding
the interferences as identified in this study cohort, all
paired samples were in zones A and B.
The total percentage of paired data values outside the
glucose prediction error of the device is around 6%, less
accurate than most of the blood gas analyzers [14]. Several
different continuous glucose monitoring devices are being
developed, using dissimilar sampling techniques and sen-
sors [1]. The reports on accuracy of other continuous glu-
cose monitoring devices show comparable accuracies,
with 95 to 100% of the paired measurements in zone A
and B of the CEG [12,13,15-18].
Even though numerous interferences were already iden-
tified in previous studies [7-9], several new ones were
identified. We were not surprised to find interferences, al-
though we did not expect to find such commonly used
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the fact that the devices were previously only ex vivo
tested in an ICU patient cohort. Furthermore, this cohort
was in another continent, where other medications and
infusion fluids are used [10]. The finding of commonly
used medications as interferences shows the importance
of external validation in different continents and coun-
tries, and maybe even hospitals. Therefore, caution is
needed with the implementation of devices.
Additionally, we encountered cartridge errors, and sys-
tem errors which occurred before connection of the de-
vice to the patient. We had to disconnect the device
frequently because of occlusion alarms, suggesting that
the device could not draw a blood sample. Sometimes
occlusion alarms could be easily overcome by flushing
the connection system. If not, manipulation of the CVC
was needed to facilitate blood draws. We are uncertain
whether these problems may persist in daily clinical
practice.
Notably, results from two patients with simultaneous
glucose infusion via another port of the CVC were ex-
cluded in the analysis. While simultaneous glucose infu-
sion via the same infusion system that is used for
measuring glucose levels should be avoided, the finding
clearly shows the risk of erroneous readings.
Any device that uses a CVC has the potential to in-
crease the risk of catheter-associated blood stream infec-
tions, especially when blood is retracted repeatedly
through the CVC. In addition, the latter could also cause
clotting in the lumen. We explicitly looked for these
clinically important complications but did not find them
in this cohort of patients. It should be noted, though,
that this study is too small to draw firm conclusions re-
garding the risk of blood stream infections or clotting.
Also, we did not find a difference in occurrence of oc-
clusion alarms between insertion site or type of cathe-
ters. In some cases of occlusion, alarms were solved by
manipulation of the CVC. It should be noted, though,
that the need for manipulation of the CVC could be a
shortcoming of the device. Second, it should be noted
that nurses were allowed to disconnect the device at any
moment an occlusion alarm occurred in the absence of
the investigators. However, it is unknown what happens
if repeated occlusion alarms occur and are resolved, that
is whether this promotes clotting of the lumen. This
needs to be investigated in future studies.
One limitation of the study is that we only collected
paired glucose measurements during working hours,
which could have prevented us from finding additional
interferences (for example, medications that are only
infused during the night). Furthermore, this was a single-
center study. Also, it is possible that additional interfer-
ences could be found when the devices are used in other
patient populations.In addition, the number of paired glucose measurements
per patient was small. An additional limitation of the study
is that most data points were in a narrow glucose range -
we only had 8 of the 484 paired measurements < 75 mg/dL
and 42 of the 484 paired measurements > 180 mg/dL. We
did not have the opportunity to assess the ability of the
device to detect severe hypoglycemia (that is, < 40 mg/dL)
as it did not occur during conduct of the study. Here, the
low incidence of hypoglycemia suggests that the nurses
were experts in insulin titration. Indeed, the nurses had
experience with the insulin infusion guideline for many
years. In addition, the blood glucose target in the local
guideline is higher compared to that in the original Leu-
ven studies, which could also have affected the incidence
of severe hypoglycemia. Furthermore, because nurses were
aware that the devices monitored the blood glucose level
in their patients frequently, it could be that they titrated
insulin more precisely. Finally, the nurses had access to all
blood glucose levels, thus also the extra ones taken for the
study. As such, nurses could also better prevent severe
hypoglycemia.Conclusion
The blood glucose measuring devices we used needed
calibration for several previously unrecognized interfer-
ences. Thereafter, accuracy of the device for measuring
plasma glucose levels in ‘our cohort’ of critically ill pa-
tients improved, but external validation is highly recom-
mended. Also, the automated blood draw system of
these devices needs further improvement to make them
of value for clinical use.Abbreviations
AMC: Academic Medical Center; APACHE: Acute Physiology and Chronic
Health Evaluation; BMI: body-mass index; CEG: Clarke error grid;
CGM: continuous glucose monitoring; CVC: central venous catheter;
IQR: interquartile range; LOS: length of stay; SAPS: Simplified Acute
Physiology Score; SD: standard deviation; YSI: Yellow Springs Instrument.Competing interest
Roosmarijn TM van Hooijdonk reported consulting work for Medtronic Inc.,
GlySure Ltd and research support from Medtronic Inc. and OptiScan
Biomedical. Tineke Winters reported consulting work for Medtronic Inc.,
GlySure Ltd and OptiScan Biomedical. James S Krinsley reports receiving
consultant fees from Medtronic Inc., Edwards Life Sciences, Roche
Diagnostics, OptiScan Biomedical and Alere and research support from
OptiScan Biomedical. Jean-Charles Preiser reported receiving consultant fees
from Medtronic Inc., Edwards Life Sciences and OptiScan Biomedical. Johan
C Fischer and Edmée C van Dongen-Lases reported no relevant disclosures.
Marcus J Schultz reported receiving consultant fees from Medtronic Inc., GlySure
Ltd., Edwards Life Sciences and Roche Diagnostics and financial support from
Medtronic Inc. and OptiScan Biomedical - all fees and financial supports were
paid to the institution. The AMC Medical Research BV received €60.000 for
covering personnel and laboratory costs associated with performing this trial.
OptiScan Biomedical provided the OptiScanner devices and cartridges free of
charge. The investigators were free to make a publication and had no restrictions
made by OptiScan Biomedical. OptiScan Biomedical was only allowed to check
the publication for company proprietary information. The authors declare that
they have no competing interests.
van Hooijdonk et al. Annals of Intensive Care 2014, 4:8 Page 8 of 8
http://www.annalsofintensivecare.com/content/4/1/8Authors’ contributions
Study concept and design: RTMvH, TW, JCF, ECD-L and MJS. Acquisition of
data: RTMvH, TW and MJS. Analysis and interpretation of data: RTMvH and
MJS. Drafting of the manuscript: RTMvH and MJS. Critical revision of the
manuscript for important intellectual content: RTMvH, TW, JCF, ECvD-L, JSK,
J-CP and MJS. All authors read and approved the final manuscript.
Author details
1Department of Intensive Care, Academic Medical Center, University of
Amsterdam, Room, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
2Department of Clinical Chemistry, Academic Medical Center, University of
Amsterdam, Amsterdam, the Netherlands. 3Division of Critical Care, Stamford
Hospital, Columbia University College of Physicians and Surgeons, Stamford,
CT, USA. 4Department of Intensive Care, Erasme University Hospital, Brussels,
Belgium. 5Laboratory of Experimental Intensive Care and Anesthesiology
(LEICA), Academic Medical Center, University of Amsterdam, Amsterdam, the
Netherlands.
Received: 7 November 2013 Accepted: 25 February 2014
Published: 6 March 2014
References
1. Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, Freire AX,
Geehan D, Kohl B, Nasraway SA, Rigby M, Sands K, Schallom L, Taylor B,
Umpierrez G, Mazuski J, Schunemann H: Guidelines for the use of an insulin
infusion for the management of hyperglycemia in critically ill patients.
Crit Care Med 2012, 40:3251–3276.
2. Schultz MJ, Harmsen RE, Spronk PE: Clinical review: strict or loose
glycemic control in critically ill patients - implementing best available
evidence from randomized controlled trials. Crit Care 2010, 14:223.
3. Finfer S, Wernerman J, Preiser JC, Cass T, Desaive T, Hovorka R, Joseph JI,
Kosiborod M, Krinsley J, Mackenzie I, Mesotten D, Schultz MJ, Scott MG,
Slingerland R, Van den Berghe G, Van Herpe T: Clinical review: consensus
recommendations on measurement of blood glucose and reporting
glycemic control in critically ill adults. Crit Care 2013, 17:229.
4. Dungan K, Chapman J, Braithwaite SS, Buse J: Glucose measurement:
confounding issues in setting targets for inpatient management.
Diabetes Care 2007, 30:403–409.
5. Miller M, Skladany MJ, Ludwig CR, Guthermann JS: Convergence of
continuous glucose monitoring and in-hospital tight glycemic control:
closing the gap between caregivers and industry. J Diabetes Sci Technol
2007, 1:903–906.
6. Aragon D: Evaluation of nursing work effort and perceptions about
blood glucose testing in tight glycemic control. Am J Crit Care 2006,
15:370–377.
7. Magarian P, Sterling B: Plasma-generating glucose monitor accuracy
demonstrated in an animal model. J Diabetes Sci Technol 2009,
3:1411–1418.
8. Jax T, Heise T, Nosek L, Gable J, Lim G, Calentine C: Automated near-continuous
glucose monitoring measured in plasma using mid-infrared spectroscopy.
J Diabetes Sci Technol 2011, 5:345–352.
9. Krinsley J, Bochicchio K, Calentine C, Bochicchio G: Glucose measurement
of intensive care unit patient plasma samples using a fixed-wavelength
mid-infrared spectroscopy system. J Diabetes Sci Technol 2012, 6:294–301.
10. Eslami S, de Keizer NF, Dongelmans DA, de Jonge E, Schultz MJ, Abu-Hanna A:
Effects of two different levels of computerized decision support on blood
glucose regulation in critically ill patients. Int J Med Inform 2012, 81:53–60.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of
disease classification system. Crit Care Med 1985, 13:818–829.
12. Mulavisala K, Gopal P, Crane B, Mackenzie A: Preliminary ICU experience of
a novel intravascular blood glucose sensor. Crit Care 2012, 16:P175.
Abstract.
13. Schierenbeck F, Owall A, Franco-Cereceda A, Liska J: Evaluation of a
continuous blood glucose monitoring system using a central venous
catheter with an integrated microdialysis function. Diabetes Technol Ther
2013, 15:26–31.
14. Inoue S, Egi M, Kotani J, Morita K: Accuracy of blood-glucose measurements
using glucose meters and arterial blood gas analyzers in critically ill adult
patients: systematic review. Crit Care 2013, 17:R48.
15. Bird S, Macken L, Flower O, Bass F, Hammond N, Webb S, Kennedy N, Baker A,
Yarad E, Chau C, Librande M, Strasma P, Finfer S: Continuous arterial andvenous glucose monitoring by quenched chemical fluorescence in ICU
patients after cardiac surgery. Crit Care 2013, 17:P461. Abstrac.
16. Nasraway SA, Ehsan A, Melanson AM, Menzie W, Trieu MQ, Berlin J, Hurley J,
Krystyniak K, Segal S: Accuracy of a novel non-invasive transdermal
continuous glucose monitor in critically ill patients. Crit Care Med 2012,
40:S305. Abstract.
17. De Block C, Manuel YKB, Van Gaal L, Rogiers P: Intensive insulin therapy in
the intensive care unit: assessment by continuous glucose monitoring.
Diab Care 2006, 29:1750–1756.
18. Goldberg PA, Siegel MD, Russell RR, Sherwin RS, Halickman JI, Cooper DA,
Dziura JD, Inzucchi SE: Experience with the continuous glucose
monitoring system in a medical intensive care unit. Diab Technol Ther
2004, 6:339–347.
doi:10.1186/2110-5820-4-8
Cite this article as: van Hooijdonk et al.: Accuracy and limitations of
continuous glucose monitoring using spectroscopy in critically ill
patients. Annals of Intensive Care 2014 4:8.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
